Legal & General Group Plc Acquires New Holdings in Zenas BioPharma, Inc. $ZBIO

Legal & General Group Plc bought a new stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the 2nd quarter, Holdings Channel.com reports. The fund bought 20,023 shares of the company’s stock, valued at approximately $508,000.

A number of other large investors have also added to or reduced their stakes in ZBIO. Vanguard Group Inc. lifted its position in shares of Zenas BioPharma by 25.0% during the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Zenas BioPharma in the 2nd quarter worth approximately $5,306,000. NEXTBio Capital Management LP bought a new position in shares of Zenas BioPharma during the 4th quarter worth approximately $11,691,000. Bank of America Corp DE raised its stake in shares of Zenas BioPharma by 723.5% during the 1st quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock worth $7,592,000 after acquiring an additional 341,187 shares in the last quarter. Finally, EcoR1 Capital LLC purchased a new stake in Zenas BioPharma during the fourth quarter valued at approximately $28,667,000.

Zenas BioPharma Stock Performance

Shares of Zenas BioPharma stock opened at $33.05 on Wednesday. The firm has a market capitalization of $2.15 billion, a P/E ratio of -3.68 and a beta of -1.04. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The company has a 50 day moving average price of $30.91 and a 200 day moving average price of $24.59. Zenas BioPharma, Inc. has a 52 week low of $13.50 and a 52 week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $15.00 million. Sell-side analysts expect that Zenas BioPharma, Inc. will post -5.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ZBIO shares. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Weiss Ratings downgraded Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Wedbush reiterated an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a report on Friday, August 14th. Guggenheim reissued a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a research report on Friday, August 14th. Finally, Morgan Stanley raised their price objective on Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.71.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.